Nuvation Bio Inc

NUVB

Company Profile

  • Business description

    Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

  • Contact

    1500 Broadway
    Suite 1401
    New YorkNY10036
    USA

    T: +1 332 208-6102

    https://www.nuvationbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    273

Stocks News & Analysis

stocks

Insignia Financial: Revised deal still attractive

The offer price is well above our fair value.
stocks

Undervalued ASX income play

Major development projects remain on schedule.
stocks

Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?

With the monetization of GenAI, here’s what we think of Alphabet’s stock

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,001.4059.900.67%
CAC 407,744.4153.81-0.69%
DAX 4024,041.90265.90-1.09%
Dow JONES (US)44,502.44179.370.40%
FTSE 1009,023.8110.820.12%
HKSE25,470.77340.741.36%
NASDAQ20,892.6981.49-0.39%
Nikkei 22541,171.321,396.403.51%
NZX 50 Index12,794.0639.68-0.31%
S&P 5006,309.624.020.06%
S&P/ASX 2008,737.2060.000.69%
SSE Composite Index3,583.121.260.04%

Market Movers